Geode Capital Management LLC Purchases 43,856 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Geode Capital Management LLC lifted its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTIFree Report) by 3.3% in the third quarter, HoldingsChannel reports. The fund owned 1,355,392 shares of the company’s stock after buying an additional 43,856 shares during the period. Geode Capital Management LLC’s holdings in Karyopharm Therapeutics were worth $1,125,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in KPTI. GSA Capital Partners LLP increased its position in Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after purchasing an additional 792,283 shares during the period. AQR Capital Management LLC grew its position in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after buying an additional 622,194 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth approximately $494,000. FMR LLC lifted its holdings in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after buying an additional 76,510 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after acquiring an additional 56,613 shares during the last quarter. Institutional investors and hedge funds own 66.44% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 1st. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Piper Sandler boosted their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Read Our Latest Stock Analysis on Karyopharm Therapeutics

Karyopharm Therapeutics Trading Down 6.9 %

Shares of Karyopharm Therapeutics stock opened at $0.72 on Friday. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $0.82. The company has a market capitalization of $90.35 million, a PE ratio of -0.63 and a beta of 0.07. Karyopharm Therapeutics Inc. has a 12 month low of $0.58 and a 12 month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTIGet Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter last year, the company posted ($0.30) EPS. Analysts predict that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

About Karyopharm Therapeutics

(Free Report)

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

Recommended Stories

Want to see what other hedge funds are holding KPTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Karyopharm Therapeutics Inc. (NASDAQ:KPTIFree Report).

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.